Review
Oncology
Linus Angenendt, Jan-Henrik Mikesch, Christoph Schliemann
Summary: The development of antibody-based therapeutics for patients with acute myeloid leukemia has been challenging due to the shared expression of antigens on leukemic blasts and hematopoietic stem and progenitor cells. However, recent years have seen the approval of the first antibody-drug conjugate for AML treatment, and promising results from other antibody-based therapeutics in clinical trials.
CANCER TREATMENT REVIEWS
(2022)
Review
Medicine, Research & Experimental
Martina Quattrone, Alessia Di Pilla, Livio Pagano, Luana Fianchi
Summary: Infections are common complications during the treatment of Acute Lymphoblastic Leukemia (ALL), with almost half of the patients developing infectious events during induction. The use of new monoclonal and bispecific antibodies and CAR-T therapy has the potential to improve overall survival and disease-free survival of patients with ALL and may also impact the epidemiology of infections in this population. This review focused on the infectious complications of Blinatumomab, Inotuzumab, Rituximab, and CAR-T therapy in both adult and pediatric ALL patients, highlighting the unique infection patterns observed in CAR-T patients.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Review
Oncology
Francesco Tamiro, Andrew P. Weng, Vincenzo Giambra
Summary: Leukemia-initiating cells (LIC) are unique cells in different types of leukemia that have self-renewing capabilities and produce tumors, which are functionally distinct from bulk leukemia cells. Current conventional treatments are not effective in eliminating LICs, hence innovative therapeutics targeting LICs hold promise for developing an effective cure for ALL.
Review
Oncology
Sargam Kapoor, Grace Champion, Aparna Basu, Anu Mariampillai, Matthew J. Olnes
Summary: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic malignancies arising from the bone marrow with poor prognosis. Recent advancements in immune therapies, including immune suppressive therapy and novel treatments like monoclonal antibodies and cellular therapeutics, have shown promise in treating these diseases.
Review
Oncology
Anna Aureli, Beatrice Marziani, Adriano Venditti, Tommaso Sconocchia, Giuseppe Sconocchia
Summary: The emergence of targeted therapies has revolutionized the management of B-lineage acute lymphoblastic leukemia, allowing for optimism in replacing traditional treatments. However, few patients currently benefit from these therapies, necessitating further research to improve outcomes, particularly in patients resistant to current treatments. This review discusses new therapeutic options, including bispecific antibodies, antibody-drug conjugates, and CAR-based therapies.
Review
Oncology
Khalil Saleh, Alexis Fernandez, Florence Pasquier
Summary: The outcome of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) has dramatically improved in the past 20 years with the introduction of tyrosine kinase inhibitors and monoclonal antibodies. These treatments have shown great efficacy in young and fit patients, leading to questioning the reliance on chemotherapy and stem cell transplantation. They can also be safely used in elderly patients, who make up the majority of Ph+ ALL patients. This review focuses on the recent changes in the management of Ph+ ALL patients and the development of new therapeutic strategies.
Review
Pharmacology & Pharmacy
Wei Li, Yayu Zhang, Ranjith Kumar Kankala, Liang Zou, Zhoujiang Chen
Summary: This review highlights the mechanisms and application status of innovative antibody and cellular-based therapies for pediatric acute lymphoblastic leukemia (ALL), and discusses the significant prospects and challenges.
Review
Biochemistry & Molecular Biology
Anca Viorica Ivanov, Mirabela Smaranda Alecsa, Roxana Popescu, Magdalena Iuliana Starcea, Adriana Maria Mocanu, Cristina Rusu, Ingrith Crenguta Miron
Summary: In the past 40 years, the survival rate for pediatric cancer has greatly improved, reaching 75-80%. However, leukemia still remains a major cause of morbidity and mortality in specific patient populations. The future of leukemia treatment lies in molecular therapies, immune therapy, and cellular therapy. Recent advances in the field have led to the development of novel therapies for childhood leukemia, including targeted therapies and immunotherapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Tina Kuenz, Alexander W. Hauswirth, Gabriele Hetzenauer, Jakob Rudzki, David Nachbaur, Normann Steiner
Summary: Improved understanding of acute lymphoblastic leukemia has led to new treatment strategies, including measurable residual disease assessment and allogeneic stem cell transplantation. Novel therapeutic opportunities, such as tyrosine-kinase inhibitors and CAR-T cells, aim to improve clinical outcomes. Despite advancements, acute lymphoblastic leukemia remains a challenging and life-threatening disease.
Article
Oncology
Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan M. O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, Alexander Neuhof, A. Douglas Laird, Anjali S. Advani
Summary: Inotuzumab ozogamicin demonstrated superior response rates, minimal/measurable residual disease negativity, longer duration of remission, and better overall survival compared to standard of care in patients with CD22 positivity >= 90%. Patients with CD22 positivity <90% showed higher response rates with inotuzumab ozogamicin therapy, but similar duration of remission and overall survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Antonella Mancusi, Francesco Zorutti, Loredana Ruggeri, Samanta Bonato, Sara Tricarico, Tiziana Zei, Roberta Iacucci Ostini, Valerio Viglione, Rebecca Sembenico, Sofia Sciabolacci, Valeria Cardinali, Massimo Fabrizio Martelli, Cristina Mecucci, Alessandra Carotti, Maria Paola Martelli, Andrea Velardi, Antonio Pierini
Summary: This study demonstrates the feasibility of using blinatumomab and DLI to treat relapses after Treg/Tcon haploidentical HSCT, and suggests that their preemptive use could improve efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Ziting Zhang, Kun Yang, Han Zhang
Summary: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and heterogeneous subtype of cancer. Recent studies have shown the important roles of leukemia-initiating cells (LICs) and leukemic niches in the initiation and progression of T-ALL, leading to the development of targeted therapies.
Review
Pharmacology & Pharmacy
Andreas Viardot, Elisa Sala
Summary: The anti-CD19 immunotherapy has shown significant potential for treating B-precursor acute lymphoblastic leukemia (B-ALL), with major advances in CD19 monoclonal antibodies, antibody-drug conjugates, bispecific T-cell engaging antibodies and adoptive cellular therapies such as CAR-Ts. Experimental anti-CD19 antibodies or CAR-Ts may overcome limitations of toxicity, rapid clearance, or resistance, suggesting promising results for novel cellular constructs.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2021)
Article
Oncology
Sisi Wang, Lijun Peng, Wenqian Xu, Yuebo Zhou, Ziyan Zhu, Yushan Kong, Stewart Leung, Jin Wang, Xiaoqiang Yan, Jian-Qing Mi
Summary: The newly designed antibodies A-319 and A-2019 showed potent antitumor effects in vitro, ex vivo, and in vivo experiments. A-319 and A-2019 are CD3/CD19 and CD3/CD19/CD20 bispecific and trispecific antibodies, respectively, capable of recruiting T cells, enhancing T-cell function, mediating B-cell depletion, and inhibiting tumor growth.
FRONTIERS OF MEDICINE
(2022)
Review
Nanoscience & Nanotechnology
Emma R. Brannon, M. Valentina Guevara, Noah J. Pacifici, Jonathan K. Lee, Jamal S. Lewis, Omolola Eniola-Adefeso
Summary: This review outlines the design aspects of polymeric particles for optimizing acute inflammation targeting, highlighting their advantages as an ideal platform for immune modulation.
NATURE REVIEWS MATERIALS
(2022)
